Bruce Kennedy ~ WeedWorthy.com ~

A group of U.S. lawmakers is calling on the U.S. Drug Enforcement Administration (DEA) of remove federal barriers on medical marijuana research and to ease new medical research on cannabis and its derivatives.

 The letter, published Thursday and addressed to Chuck Rosenberg, the DEA’s Acting Administrator, was signed by Senator Kirsten Gillibrand (D-NY), along with Senators Cory A. Booker (D-NJ), Jeffrey A. Merkley (D- OR), Barbara Boxer (D-CA), and U.S. Representatives Earl Blumenauer (D-OR), Dana Rohrabacher (R-CA), Jared Polis (D-CO) and Ted Lieu (D-CA).

It also requested a meeting with Administrator Rosenberg if he does not take action on medical marijuana.

The Senators and Representatives noted that more than half of U.S. states have passed laws legalizing medical marijuana, while 42 states allow the medicinal use of cannabis-derived substances.

“Nevertheless, federal policies continue to hinder medical researchers’ ability to study the benefits of cannabis, particularly as a therapy for conditions which are resistant to other forms of treatment,” their letter continued.

It also cited information from the U.S. Department of Health and Human Services (HHS), which has reportedly determined “that medication naturally derived from the cannabis plant has a medical use.”

Just last week, several of the senators cited in the Thursday letter were signatories on another letter to the DEA; requesting an update on the DEA’s decision about whether to adjust marijuana's classification as a Schedule I drug under the Controlled Substances Act (CSA).

Drugs with a Schedule 1 classification are currently considered as having "no accepted medical use and a high potential for abuse."

According to that earlier letter, the DEA previously indicated that a new scheduling determination would occur in the "first half of 2016."

“While we appreciate the DEA’s willingness to maintain an open dialogue with our offices, the senators continued in their June 23 letter, "we are concerned that ‘the first half of 2016’ is coming to a close and no rescheduling announcement has been made.”

The senators added they believe the rescheduling of cannabis and the resolution of regulatory barriers to research on marijuana “is a time-sensitive matter that requires immediate action,” asking for a briefing on the DEA’s decision regarding rescheduling “no later than July 5.”

Recent News Articles

Friday February 28

Colorado’s first licensed cannabis R&D firm to study marijuana’s effect on Alzheimer’s disease

in Medical News

by Bruce Kennedy - Editor in Chief

A Denver-based company hopes to be the state’s first to study the effects of marijuana…

2516 hits

Friday February 28

Texas state crime labs won’t test suspected marijuana in low-level cases - Cannabis News

in Law & Crime

by Bruce Kennedy - Editor in Chief

The Texas Department of Public Safety said last week that it would not perform testing…

2517 hits

Monday March 02

Cannabis And Lou Gehrig’s Disease: Here’s What You Should Know - Cannabis News

in Medical News

by Bruce Kennedy - Editor in Chief

Considering the neuroprotective effects of cannabinoids and the anti-spastic effects of cannabinoids in multiple sclerosis…

1534 hits

Monday March 02

Bill To Legalize Marijuana Sales Officially Passes Vermont House Of Representatives - Cannabis News

in Politics

by Bruce Kennedy - Editor in Chief

The Vermont House of Representatives finalized its approval of a bill to legalize the retail…

1473 hits

Monday March 02

Study reveals antibiotic potential of cannabis compound - Cannabis News

in Science

by Bruce Kennedy - Editor in Chief

A compound made by cannabis plants has been found to wipe out one of the…

1437 hits